Frontotemporal Dementia (FTD)

Table of Contents

1. Overview and Significance
2. Clinical Variants
3. Behavioral Variant FTD (bvFTD)
4. Primary Progressive Aphasia Variants
5. Neuropathology
6. Genetics and Familial FTD
7. FTD-ALS Overlap
8. Diagnosis and Biomarkers
9. Treatment and Management
10. Caregiving Challenges
11. Key Research Papers
12. Featured Videos
13. Connections

Overview and Significance

Frontotemporal dementia (FTD) — also called frontotemporal lobar degeneration (FTLD) — is the second most common cause of early-onset dementia, after Alzheimer's disease, accounting for roughly 10–15% of all dementia cases overall and up to 20% of cases with onset before age 65. Typical onset falls between 45 and 65 years, a full decade earlier than the peak of Alzheimer's disease, making FTD particularly devastating for working adults and their families.

The disorder is defined by progressive, disproportionate atrophy of the frontal and temporal lobes. Because these regions govern personality, judgment, language, and social behavior — not episodic memory — FTD presents in ways that can be bewildering and deeply stigmatizing before a diagnosis is reached. Patients may be misidentified as having a psychiatric illness (depression, bipolar disorder, schizophrenia) for years before the neurodegenerative cause is recognized. Mean survival from symptom onset is 6–11 years, depending on phenotype and underlying pathology.

FTD is not a single disease but a clinical syndrome with multiple subtypes linked to distinct neuropathological and genetic causes. No disease-modifying therapy currently exists, and management centers on symptom control and caregiver support.

Clinical Variants

Three major clinical syndromes are recognized under the FTD umbrella, each reflecting predominant atrophy in different frontal or temporal regions:

• Behavioral variant FTD (bvFTD) — frontal-predominant; most common (~60% of FTD cases)
• Nonfluent/agrammatic primary progressive aphasia (nfvPPA) — left premotor/Broca's area-predominant
• Semantic variant PPA (svPPA), also called semantic dementia — bilateral temporal pole-predominant, left greater than right

Each variant has a characteristic neuroimaging signature, biomarker profile, and — in many cases — underlying molecular pathology that differs from the others. Distinguishing these variants matters for prognosis and eventual access to targeted therapies.

Behavioral Variant FTD (bvFTD)

bvFTD is the most frequently diagnosed FTD syndrome and the one most often mistaken for a psychiatric disorder. The International Consensus Criteria (Rascovsky et al., 2011) require three or more of the following core features for a "probable" diagnosis:

• Disinhibition — socially inappropriate actions, impulsivity, loss of tact or social niceties
• Apathy or inertia — reduced motivation, loss of drive, decreased spontaneous activity
• Loss of empathy or sympathy — diminished responsiveness to the emotional needs of others
• Perseverative, stereotyped, or compulsive behaviors — repetitive movements, rituals, verbal stereotypies (catch-phrases repeated dozens of times daily), rigid routines
• Hyperorality and dietary changes — craving for sweets, carbohydrates, or unusual foods; hyperphagia; oral exploration of non-food objects
• Executive dysfunction — planning, abstraction, and working memory deficits, out of proportion to episodic memory impairment

A critical distinguishing feature from Alzheimer's disease is relative early preservation of episodic memory. Patients with bvFTD can often recall appointments and recent events far better than their behavioral disintegration would suggest. Neuroimaging classically shows bilateral (often asymmetric) frontal and anterior temporal atrophy with frontal hypometabolism on FDG-PET.

The "bvFTD phenocopy" syndrome — patients meeting clinical criteria for bvFTD who have no progressive neurodegeneration on imaging or biomarkers and do not decline — is a recognized diagnostic pitfall, most often representing a psychiatric or functional condition.

Primary Progressive Aphasia Variants

Primary progressive aphasia (PPA) is characterized by a selective, progressive deterioration of language with relative preservation of other cognitive domains in the early years. Two major PPA subtypes fall under the FTD spectrum:

Nonfluent/Agrammatic PPA (nfvPPA)

nfvPPA results primarily from left premotor cortex and inferior frontal gyrus (Broca's area) atrophy. Core features include:

• Effortful, halting, nonfluent speech production
• Agrammatism — simplification of syntactic structure, omission of grammatical morphemes
• Apraxia of speech — distorted phoneme substitutions and motor-speech errors, separate from agrammatism
• Relative preservation of single-word comprehension and object knowledge

Over years, patients often progress to near-mutism and, in many cases, develop a PSP-like or corticobasal syndrome movement phenotype. The underlying pathology is predominantly tau (4R tauopathy: PSP-tau or CBD-tau), distinguishing it from svPPA.

Semantic Variant PPA (svPPA) — Semantic Dementia

svPPA is the most distinctive FTD language syndrome and the one with the most predictable pathology (TDP-43 type C in nearly all cases). Bilateral temporal pole atrophy, left greater than right, underlies the hallmark features:

• Progressive anomia — loss of word meaning rather than word retrieval per se; patients cannot name objects, people, or concepts
• Impaired single-word comprehension — "What is a rhinoceros?" draws a blank
• Surface dyslexia and dysgraphia — spelling errors driven by phonology (e.g., "pint" read as "pint" to rhyme with "mint")
• Fluent, grammatically intact but semantically empty speech
• Face and object recognition deficits in advanced disease

Episodic memory and visuospatial skills are often well preserved initially, contrasting sharply with the semantic knowledge loss. Behavioral changes resembling bvFTD commonly emerge as the disease progresses.

Neuropathology

FTD is neuropathologically heterogeneous. Three major protein inclusions account for nearly all cases of FTLD:

TDP-43 Proteinopathy (FTLD-TDP)

TAR DNA-binding protein 43 kDa (TDP-43) accumulations are the most common pathology, found in ~50% of FTLD cases. Four subtypes (A–D) differ in inclusion morphology and distribution, and they track closely with genetics and clinical presentation:

• Type A — bvFTD or nfvPPA; associated with GRN mutations and FTLD-ALS
• Type B — bvFTD with motor neuron disease (FTLD-MND); strongly linked to C9orf72 expansion
• Type C — svPPA; almost exclusively; sporadic
• Type D — bvFTD with inclusion body myopathy; associated with VCP mutations

Tau Proteinopathy (FTLD-tau)

Tau inclusions (~45% of FTLD) include several distinct subtypes:

• Pick's disease — 3R tau; classic "Pick bodies" (rounded neuronal inclusions) in dentate gyrus and frontal/temporal cortex; often bvFTD or svPPA
• Corticobasal degeneration (CBD) — 4R tau; astrocytic plaques; presents as corticobasal syndrome (CBS) or nfvPPA
• Progressive supranuclear palsy (PSP) pathology — 4R tau; astrocytic tufts; may present as PSP-Richardson's or nfvPPA

FUS Proteinopathy (FTLD-FUS)

FUS (fused in sarcoma) inclusions account for ~5% of FTLD and are predominantly associated with young-onset bvFTD (onset before age 40), often without a family history. FUS pathology is notable for its severity of striatal atrophy.

Genetics and Familial FTD

FTD has a stronger hereditary component than Alzheimer's disease — roughly 40% of patients have a positive family history. Three genes account for the large majority of familial FTD:

C9orf72 Hexanucleotide Repeat Expansion

A GGGGCC hexanucleotide repeat expansion in the first intron of C9orf72 is the single most common genetic cause of familial FTD and familial ALS in populations of European ancestry, accounting for approximately 25% of familial FTD cases overall. The normal repeat count is typically fewer than 30; pathogenic expansions carry hundreds to thousands of repeats. The expansion causes disease through both loss-of-function (reduced C9orf72 protein) and gain-of-toxic-function mechanisms (RNA foci + dipeptide repeat proteins). The C9orf72 expansion is the molecular bridge between FTD and ALS (see FTD-ALS Overlap section).

GRN (Progranulin)

Loss-of-function mutations in the GRN gene reduce progranulin levels by ~50% (haploinsufficiency). Progranulin is a lysosomal growth factor critical for microglial function and neuronal survival. GRN mutations account for ~10% of familial FTD and cause FTLD-TDP type A pathology. Plasma progranulin can be used as a biomarker — levels below ~60 ng/mL are highly sensitive for GRN mutation carriers. This has direct therapeutic relevance: progranulin-replacement strategies (AL001/latozinemab, gene therapy) are under active investigation.

MAPT (Microtubule-Associated Protein Tau)

MAPT mutations cause FTLD-tau (Pick's disease, CBD-tau, or PSP-tau pathology depending on the specific mutation). The H1 haplotype of MAPT increases risk for sporadic PSP and CBD. Autosomal dominant MAPT missense mutations (e.g., P301L, R406W, N279K) cause familial bvFTD or parkinsonism-dementia syndromes.

Less Common Genetic Causes

• VCP — causes inclusion body myopathy + Paget's disease of bone + FTD (IBMPFD); TDP-43 type D pathology
• CHMP2B — rare; associated with frontotemporal dementia linked to chromosome 3 (FTD-3)
• TARDBP, FUS — mutations in the TDP-43 and FUS genes themselves, typically presenting with FTD-MND overlap

FTD-ALS Overlap

One of the most important conceptual advances in FTD research has been the recognition that FTD and amyotrophic lateral sclerosis (ALS) exist on a disease continuum rather than as separate diseases. Approximately 15–20% of FTD patients develop motor neuron disease features (weakness, fasciculations, EMG evidence of denervation), and approximately 50% of ALS patients have some degree of cognitive or behavioral impairment; 10–15% of ALS patients meet full criteria for bvFTD.

The unifying molecular link is the C9orf72 expansion, which can cause pure FTD, pure ALS, or a combined FTD-ALS syndrome, all within the same family. Additional shared pathological proteins (TDP-43, FUS, UBQLN2) reinforce the spectrum concept. The FTD-ALS overlap has profound implications for clinical trials — excluding patients with any motor neuron features from FTD trials (or vice versa) risks missing key patient populations.

From a caregiving perspective, FTD-ALS is particularly burdensome: behavioral and personality changes from FTD compound the progressive paralysis and swallowing difficulty of ALS, often leaving caregivers without support from a patient who can no longer engage emotionally.

Diagnosis and Biomarkers

FTD diagnosis remains primarily clinical, supported by neuroimaging. A key early step is excluding treatable mimics (thyroid disease, B12 deficiency, NPH, CNS vasculitis, paraneoplastic encephalitis, psychiatric disorders). Standard workup includes:

• Neuropsychological testing — executive function battery, language assessment, memory testing (to document relative memory preservation); Addenbrooke's Cognitive Examination, FAB (Frontal Assessment Battery)
• MRI brain — frontal and/or temporal lobe atrophy; asymmetric atrophy is common and diagnostically informative (temporal poles in svPPA, left perisylvian in nfvPPA, bilateral frontal in bvFTD)
• FDG-PET — frontal and/or anterior temporal hypometabolism, often more sensitive than structural MRI in early disease
• Amyloid PET or CSF Alzheimer's biomarkers — to exclude Alzheimer's disease (negative amyloid strengthens FTD diagnosis)

Emerging Fluid Biomarkers

Blood and CSF biomarkers are transforming FTD diagnosis and trial readiness:

• Neurofilament light (NfL) — elevated in plasma and CSF in all FTD variants; the highest NfL levels occur in FTD-ALS and C9orf72 carriers; useful for tracking progression and as a trial endpoint, though not specific to FTD
• GFAP (glial fibrillary acidic protein) — elevated in plasma; reflects astrocytic activation; higher in FTD than in psychiatric mimics
• Plasma progranulin — directly diagnostic for GRN mutation carriers; low levels indicate haploinsufficiency
• Phospho-tau 181/217/231 ratios — helpful for distinguishing FTD (tau negative) from Alzheimer's disease (tau positive); plasma p-tau217 is particularly discriminating
• TDP-43 biomarkers — still early-stage but fragments of TDP-43 in CSF/plasma under active investigation

Treatment and Management

As of 2024, no disease-modifying therapy has been approved for FTD. Multiple mechanism-targeting trials have failed, including the anti-tau antisense oligonucleotide gosuranemab (discontinued in PSP/CBS) and the LRRK2 inhibitor trials. Active investigational approaches include:

• Progranulin replacement for GRN mutation carriers — latozinemab (AL001), an anti-sortilin monoclonal antibody that raises progranulin; Phase 3 trial ongoing
• C9orf72-targeted therapies — antisense oligonucleotides and small molecules targeting RNA foci and dipeptide repeat proteins
• Gene therapy for GRN haploinsufficiency — direct CNS progranulin delivery via AAV

Symptomatic Pharmacotherapy

Current drug use is off-label and targets behavioral symptoms:

• SSRIs (sertraline, fluvoxamine, paroxetine) — modest evidence for reducing disinhibition, compulsive behaviors, and emotional lability; generally well tolerated; first-line for behavioral bvFTD
• Trazodone — randomized trial evidence (Lebert et al., 2004) supports benefit for behavioral symptoms; 50–150 mg/day
• Low-dose antipsychotics (quetiapine, olanzapine, risperidone) — used cautiously for severe agitation or psychosis; avoid in patients with motor features (parkinsonism risk)
• Avoid acetylcholinesterase inhibitors and memantine — no evidence of benefit in FTD (unlike Alzheimer's); may worsen behavioral symptoms
• Avoid benzodiazepines — increased fall risk, cognitive worsening, paradoxical agitation

Non-Pharmacological Interventions

Structured daily routine, physical exercise, and environmental simplification reduce behavioral episodes. Speech-language therapy can prolong functional communication in PPA variants; augmentative communication devices can be introduced proactively. Swallowing evaluation (VFSS) becomes critical in advanced disease.

Caregiving Challenges

FTD is widely regarded by dementia specialists as one of the most caregiver-demanding conditions in all of neurology. Unlike Alzheimer's disease — where patients often remain warm and recognizable until late stages — bvFTD erases the patient's personality, empathy, and social judgment early, leaving caregivers grieving the loss of a person who is still physically present.

Key challenges unique to FTD caregiving include:

• Legal and financial issues arise early — disinhibition leads to impulsive financial decisions, gambling, sexual misconduct, shoplifting, and driving offenses; capacity assessment and legal protections (power of attorney, conservatorship) are often needed years before they would be in Alzheimer's disease
• Psychiatric misdiagnosis delays — the average time from symptom onset to correct FTD diagnosis is 3–4 years; families often report being told the patient has depression, a personality disorder, or a midlife crisis
• Loss of empathy is personally devastating — caregivers describe feeling invisible or unloved by a partner who is biologically unable to process their emotional needs
• Young onset impacts finances — onset at 50–60 years means the patient and often their caregiver are still in the workforce; disability insurance and early Social Security Disability are essential to pursue
• Support resources — the Association for Frontotemporal Degeneration (AFTD) offers disease-specific education, a helpline (1-866-507-7222), and support groups for caregivers

Key Research Papers

1. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–2477.
   PMID: 21810890
2. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–1014.
   PMID: 21325651
3. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256.
   PMID: 21944778
4. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–919.
   PMID: 16862116
5. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1–4.
   PMID: 19924424
6. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416–438.
   PMID: 23931993
7. Seeley WW, Miller BL. Behavioral frontotemporal dementia. Continuum (Minneap Minn). 2022;28(3):728–751.
   PMID: 35678397
8. Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol. 2017;13(7):406–419.
   PMID: 28548104
9. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007;21(4):S79–87.
   PMID: 18090425
10. Knopman DS, Roberts RO. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci. 2011;45(3):330–335.
    PMID: 21336679
11. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–359.
    PMID: 15178953
12. Bott NT, Radke A, Stephens ML, Kramer JH. Frontotemporal dementia: diagnosis, deficits and management. Neurodegener Dis Manag. 2014;4(6):439–454.
    PMID: 25531687

PubMed searches:
Frontotemporal dementia diagnosis treatment (PubMed)
FTLD TDP-43 tau pathology (PubMed)
C9orf72 FTD ALS expansion (PubMed)

Featured Videos

Connections

• Normal Pressure Hydrocephalus (NPH)
• Progressive Supranuclear Palsy (PSP)
• Vascular Dementia
• Alzheimer's Disease
• Amyotrophic Lateral Sclerosis (ALS)
• Parkinson's Disease
• Corticobasal Syndrome
• Neurology Diseases